• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

2.860 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
July 31, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Avantor Stock Earns 84 RS Rating ↗
July 30, 2024
Avantor stock had its Relative Strength (RS) Rating upgraded from 78 to 84 Tuesday amid positive Q2 earnings results. 
Via Investor's Business Daily
News headline image
Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
July 30, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
July 17, 2024
New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast Cancer 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Key Takeaways From Myriad Genetics Analyst Ratings ↗
June 27, 2024
 
Via Benzinga
News headline image
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
July 11, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
July 09, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
The 3 Best Gene Editing Stocks to Buy in July 2024 ↗
July 08, 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. 
Via InvestorPlace
News headline image
Myriad Genetics Earns 2024 Great Place To Work® Certification™
July 02, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
June 24, 2024
New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
June 18, 2024
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including 
Via MarketBeat
News headline image
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
June 11, 2024
New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancer 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
June 04, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
June 03, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
May 30, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
May 16, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life ↗
May 10, 2024
Genomics is the future of medicine, creating big opportunity for some of the top genomics stock picks to buy today. 
Via InvestorPlace
News headline image
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
May 23, 2024
Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday ↗
May 08, 2024
 
Via Benzinga
News headline image
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
May 08, 2024
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
May 08, 2024
 
Via Benzinga
News headline image
MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q1 2024 ↗
May 07, 2024
MYGN stock results show that Myriad Genetics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
May 07, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
May 07, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
April 30, 2024
Management will also participate in four upcoming investor healthcare conferences 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
April 17, 2024
80% of people diagnosed with anxiety, depression report losing years or decades of time 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
April 16, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
April 09, 2024
Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight test 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
March 21, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
March 20, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap